Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 11:26 ET | Source: Zelluna ASA

Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer.

Forventer første kliniske data fra midten av 2026Markerer et viktig skritt mot skalerbare, tilgjengelige "off-the-shelf" celleterapier for solide kreftformer Oslo, Norge, 17. desember 2025 – Zelluna...
December 17, 2025 11:26 ET | Source: Zelluna ASA

Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours

On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a...
December 16, 2025 06:37 ET | Source: Zelluna ASA

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Strong preclinical data support planned clinical trial initiation in 2026 Oslo, Norway, 16 December 2025– Zelluna (OSE: ZLNA), a company developing off-the-shelf cell therapies for cancer, today...
December 12, 2025 07:02 ET | Source: Zelluna ASA

Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial

On track to file a Clinical Trial Application (CTA) by year end 2025, with initial clinical data expected mid-2026Important step in developing scalable and accessible ‘off-the-shelf’ cell therapy for...
December 09, 2025 03:36 ET | Source: Zelluna ASA

Zelluna ASA: Cancellation of subsequent repair offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION...
December 08, 2025 12:36 ET | Source: Zelluna ASA

Zelluna ASA - Mandatory notification of trade

Reference is made to the private placement (the "Private Placement") and the retail offering through PrimaryBid announced by Zelluna ASA on 3 November 2025. Please see the attached PDMR-form related...
December 08, 2025 07:52 ET | Source: Zelluna ASA

Zelluna ASA: New share capital registered

Oslo, Norway, 8 December, 2025: Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the successful private placement of 5,500,000 new...
November 28, 2025 01:50 ET | Source: Zelluna ASA

Zelluna ASA Announces Appointment of Geir Christian Melen as New Chief Financial Officer

Oslo, Norway, 28 November 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of cancer, today...
November 27, 2025 02:35 ET | Source: Zelluna ASA

Zelluna ASA: Disclosure of large shareholding

Reference is made to the stock exchange announcement made by Zelluna ASA (the "Company") on 3 November 2025 regarding the allocation of 5,500,000 new shares in the Company in a private placement (the...
November 25, 2025 05:32 ET | Source: Zelluna ASA

Zelluna ASA – Extraordinary General Meeting held on November 25, 2025

Oslo, November 25, 2025: Zelluna ASA held its extraordinary general meeting today November 25, 2025. All the matters on the agenda were approved. The minutes from the meeting are enclosed and...